Molecular regulation of endothelial glycocalyx-mediated transcytosis
Active Project Grant Awarded Last action
- Award ID
- R35GM161201
- Recipient
-
Seattle Institute For Biomedical And Clinical Research UEI DRRKVZVXSND3
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $374,550
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 8% complete
- Place of performance
- Seattle, WA 98108, USA
Award details come from USAspending.gov.
About this award
The National Institute of General Medical Sciences awarded the Seattle Institute For Biomedical And Clinical Research $374,550 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate molecular regulation of endothelial glycocalyx-mediated transcytosis.
The work characterizes molecular components that regulate transendothelial transport of chemokines and viral proteins across endothelial cell barriers, with emphasis on tissue-specific and vascular-zone-specific differences in transport regulation. The research employs radiochemical-based assays to measure blood-to-tissue transport rates of proteins in vivo and in situ, alongside cell-based assays that preserve heparan sulfate-dependent chemokine transport processes resembling those observed in living organisms. The project focuses on heparan sulfate as a major glycocalyx component and identifies the molecular machinery underlying selectivity of transport functions across different tissues.
Performance occurs in Seattle, Washington, with a period of performance from June 1, 2026, through March 31, 2031. The assistance type is a Project Grant.
Description
- Abstract
- Endothelial cells are the primary regulatory interface for the exchange of substances between blood and tissues. The luminal (blood-facing) surface of endothelial cells contains a complex, carbohydrate rich structure called the glycocalyx which is the first surface of interactions between circulating components and endothelial cells. However, the involvement of glycocalyx components in the binding, uptake, and transport of substances across endothelial barriers is inadequately understood, particularly in vivo. Our research over the last 5 years has elucidated fundamental regulatory aspects of glycocalyx-mediated transendothelial transport of chemokines and viral proteins. We have observed that there are tissue-specific differences in transport regulation, and that transport can occur selectively in different vascular zones, suggesting that the molecular machinery of the glycocalyx that regulates transport also varies by tissue and vascular zone. A particular strength of our approach is our unique ability to conduct highly sensitive and rigorous radiochemical-based assays which enable US to calculate blood-to-tissue transport rates of proteins in vivo and in situ, as well as other pharmacological parameters such as vascular binding, biodistribution, and clearance. We have also developed cell-based assays that are amenable for studies of glycocalyx-dependent transendothelial transport, with intact HS-dependent chemokine transport processes resembling those in vivo. In the next 5 years, our main goal is to characterize the molecular components that regulate the basic biological process of glycocalyx-mediated transendothelial transcytosis, including those that confer tissue specificity of transport functions. As heparan sulfate (HS) is a major component of the glycocalyx which regulates the transendothelial transport of chemokines, we will focus on the molecular components of HS- mediated chemokine transport as an initial example. We hypothesize that chemokines undergo endothelial transcytosis by binding to HS on membrane-attached HS proteoglycans (hspgs i.e. syndecans or glypicans), which are subsequently endocytosed and routed through vesicular pathways to the abluminal side, where they are released. Our research plan entails the implementation of spatial transcriptomics, proteomics, glycomics, and cell biology to relate our in vivo functional results to the expression and composition of endothelial hspgs in different tissues and vascular zones. We will pair these results with functional assays in vitro using pharmacologic and molecular approaches to identify the hspgs and attached HS moieties that are regulating transendothelial transport. We will additionally characterize transcytotic routing mechanisms of hspgs and their bound ligands in vitro using fluorescent imaging, pharmacologic, and molecular approaches. Achievement of these goals would advance the general knowledge of endothelial cell biology and endocytic/transcytotic transport mechanisms. Our findings would also have broad applications in studying biological processes that involve HS/ligand interactions in health and disease, and for drug development.
Quick answers
Who received award R35GM161201?
R35GM161201 was awarded to Seattle Institute For Biomedical And Clinical Research by National Institute of General Medical Sciences (National Institutes of Health) on June 1, 2026.
How much is award R35GM161201 worth?
$374,550 has been obligated on R35GM161201.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award